retatrutide weight loss clinical trials retatrutide Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial Tirzepatide vs. Retatrutide: Key Differences

In addition to having a higher cancer incidence, patients with T2D have been shown to have poorer cancer prognosis than patients without T2D (4244)

2026 ( Frontiers in Endocrinology ), Managing nausea and vomiting in GLP-1-based obesity therapies

A new survey report from the International Foundation of Employee Benefit Plans reveals results from a group of Canadian employers regarding considerations and coverage for glucagon-like peptide-1 (GLP-1) drugs, which have historically been used to treat diabetes and are increasingly being used to treat obesity

Some women can extend cycles to 8 weeks or increase doses slightly, but this should only be done with careful monitoring for any signs of voice deepening, facial hair growth, or clitoral enlargement

The full therapeutic dose